The Experts below are selected from a list of 11778 Experts worldwide ranked by ideXlab platform

Xiaoxue Wang - One of the best experts on this subject based on the ideXlab platform.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of Clinical Endocrinology & Metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    CONTEXT Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. PURPOSE To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. METHODS Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. RESULTS Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). CONCLUSION Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications.

Meng Wang - One of the best experts on this subject based on the ideXlab platform.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of Clinical Endocrinology & Metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    CONTEXT Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. PURPOSE To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. METHODS Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. RESULTS Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). CONCLUSION Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications.

Priscilla L Yang - One of the best experts on this subject based on the ideXlab platform.

  • Lipid Metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis c virus
    Journal of the American Chemical Society, 2012
    Co-Authors: Mary A Rodgers, Valerie A Villareal, Esperance A Schaefer, Lee F Peng, Kathleen E Corey, Raymond T Chung, Priscilla L Yang
    Abstract:

    Hepatitis C virus (HCV) infection has been clinically associated with serum Lipid abnormalities, yet our understanding of the effects of HCV on host Lipid metabolism and conversely the function of individual Lipids in HCV replication remains incomplete. Using liquid chromatography-mass spectrometry (LC-MS) Metabolite profiling of the HCV JFH1 cell culture infection model, we identified a significant steady state accumulation of desmosterol, an immediate precursor to cholesterol. Pharmacological inhibition or RNAi-mediated depletion of DHCR7 significantly reduced steady-state HCV protein expression and viral genomic RNA. Moreover, this effect was reversed when cultures were supplemented with exogenous desmosterol. Together, these observations suggest an intimate connection between HCV replication and desmosterol homeostasis and that the enzymes responsible for synthesis of desmosterol may be novel targets for anti-viral design.

  • Identification of an overabundant cholesterol precursor in hepatitis B virus replicating cells by untargeted Lipid Metabolite profiling.
    Journal of the American Chemical Society, 2009
    Co-Authors: Mary A Rodgers, Alan Saghatelian, Priscilla L Yang
    Abstract:

    Viruses rely upon host Lipid metabolic pathways for successful replication, and there is increasing interest in these pathways as novel therapeutic targets for antiviral drug discovery. Despite this, relatively little is known about the impact of viral infection on cellular Lipid metabolism, and the specific Lipid Metabolites utilized by viruses have not yet been examined. We have applied liquid chromatography−mass spectroscopy (LC−MS) based untargeted Metabolite profiling to identify Lipid Metabolites whose steady-state abundance is significantly altered by replication of hepatitis B virus (HBV), a major human pathogen. Untargeted Metabolite profiling indicated that although major Lipid classes were unaffected by HBV, an ion of 367 m/z was overabundant in HBV+ cells by 18-fold. As shown by ion fragmentation mass spectrometry and coinjection with standard, the identity of this ion is 7-dehydrocholesterol (7-DHC), an immediate dehydrogenated precursor to cholesterol. While cholesterol has previously been d...

Qingfeng Liu - One of the best experts on this subject based on the ideXlab platform.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of Clinical Endocrinology & Metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    CONTEXT Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. PURPOSE To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. METHODS Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. RESULTS Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). CONCLUSION Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications.

Wei Gong - One of the best experts on this subject based on the ideXlab platform.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

  • High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly.
    The Journal of Clinical Endocrinology & Metabolism, 2020
    Co-Authors: Meng Wang, Shizhe Guo, Xiaoqing Shao, Lei Feng, Wei Gong, Qingfeng Liu, Vladimir Melnikov, Xiaoxue Wang
    Abstract:

    CONTEXT Metabolic disorders, especially dysregulated Lipid metabolism, increase the risk of cardiovascular mortality in acromegaly. Previous studies measuring plasma macromolecular Lipids have yielded conflicting results. PURPOSE To explore the plasma Lipid Metabolite profiles by metabolomics analysis and identify potential Metabolites associated with cardiac function in acromegaly. METHODS Plasma was obtained from 80 newly diagnosed, untreated patients with acromegaly and 80 healthy controls. Echocardiography was performed. Based on the results of an oral glucose tolerance test (OGTT), patients were categorized into 2 groups: normal glucose tolerance (NGT, n = 28) and impaired glucose tolerance or diabetes mellitus (IGT/DM, n = 52). High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based metabolomics analysis was conducted. Data were processed by principal components analysis (PCA), orthogonal partial least square-discriminant analysis (OPLS-DA), and MetaboAnalyst 4.0. Associations between metabolic substances and cardiovascular parameters were also explored. RESULTS Metabolomics uncovered a distinct metabolic pattern between acromegaly and healthy controls, and perturbed pathways mainly include glycerophosphoLipid metabolism, sphingoLipid metabolism, as well as linoleic acid metabolism. Collective analysis showed that phosphatidylethanolamine (PE) (22:6/16:0) was positively correlated with LV mass, while lysophosphatidylcholine (LysoPC) (16:0) was positively correlated with fractional shortening (FS) and left ventricle ejection fraction (LVEF). CONCLUSION Patients with acromegaly have distinct Lipid Metabolite profiling, while PE (22:6/16:0) and LysoPC (16:0) are correlated with cardiac structure and function, which may contribute to the risk of cardiovascular complications.